NEW YORK (GenomeWeb) – Interpace Diagnostics today announced that it received notification from the Nasdaq on Wednesday that it has regained compliance with a listing requirement calling for a minimum closing bid price on the company's stock of at least $1 per share.
In April, the molecular diagnostics company regained compliance with another listing requirement calling for at least $2.5 million in stockholder equity. In December 2016, Interpace effected a 1-for-10 reverse stock split, also to comply with the $1 minimum bid rule.
Earlier this week, Interpace and Laboratory Corporation of America announced an extended deal for LabCorp to offer two Interpace molecular thyroid tests.
In early morning trading today, Interpace's shares were down a fraction of 1 percent at $1.34.